Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
J Med Virol. 2015 Feb;87(2):287-95. doi: 10.1002/jmv.24053. Epub 2014 Aug 25.
To predict the impact of current vaccines on cervical cancer and for the improvement of screening programs, regional data on distribution of human papillomavirus (HPV) types in women with or without cervical cancer is crucial. The present meta-analysis intend to comprehensively evaluate the HPV burden in women with invasive cervical cancer, high-grade squamous intraepithelial lesion (cervical intraepithelial neoplasia 2 and 3), low-grade squamous intraepithelial lesion (cervical intraepithelial neoplasia 1), atypical squamous cells of undetermined significance and normal cytology, as these data will help decision making in regards with screening programs and HPV vaccination in Iran. To determine the HPV prevalence and type distribution in Iranian women with or without cervical cancer, 20 published studies were included in this meta-analysis. In total, 713, 124, 104, 60, and 2577 women invasive cervical cancer, high-grade squamous intraepithelial lesion (cervical intraepithelial neoplasia 2 and 3), low-grade squamous intraepithelial lesion (cervical intraepithelial neoplasia 1), atypical squamous cells of undetermined significance and normal were reviewed, respectively. Overall HPV prevalence in women with invasive cervical cancer, high-grade squamous intraepithelial lesion (cervical intraepithelial neoplasia 2 and 3), low-grade squamous intraepithelial lesion (cervical intraepithelial neoplasia 1), atypical squamous cells of undetermined significance and normal cytology were 77.4%, 71.8%, 65.3%, 61.7%, and 8.4%, respectively. The six most common types were HPV 16, 18, 6/11, 31, and 33; among them HPV 16 was the most frequent type in all five different groups. According to this study, it was estimated that HPV vaccines could have a great impact on prevention of cervical cancer in Iran. In conclusion, this meta-analysis highlights the necessity of introducing vaccination program in Iran.
为了预测当前疫苗对宫颈癌的影响,并改善筛查计划,了解特定地区 HPV 型别在宫颈癌患者及癌前病变患者中的分布情况至关重要。本荟萃分析旨在全面评估浸润性宫颈癌、高级别鳞状上皮内病变(宫颈上皮内瘤变 2 级和 3 级)、低级别鳞状上皮内病变(宫颈上皮内瘤变 1 级)、非典型鳞状细胞意义不明确及正常细胞学患者中的 HPV 负担,这将有助于为伊朗的筛查计划和 HPV 疫苗接种决策提供依据。为了确定伊朗宫颈癌患者及癌前病变患者中 HPV 的流行率和型别分布,我们纳入了 20 项已发表的研究进行荟萃分析。总共纳入了 713 例浸润性宫颈癌、124 例高级别鳞状上皮内病变(宫颈上皮内瘤变 2 级和 3 级)、104 例低级别鳞状上皮内病变(宫颈上皮内瘤变 1 级)、60 例非典型鳞状细胞意义不明确及 2577 例正常细胞学患者。浸润性宫颈癌、高级别鳞状上皮内病变(宫颈上皮内瘤变 2 级和 3 级)、低级别鳞状上皮内病变(宫颈上皮内瘤变 1 级)、非典型鳞状细胞意义不明确及正常细胞学患者中 HPV 的总体流行率分别为 77.4%、71.8%、65.3%、61.7%和 8.4%。最常见的 6 种 HPV 型别为 HPV 16、18、6/11、31 和 33,其中 HPV 16 在所有 5 个不同组别中均为最常见的型别。基于本研究结果,HPV 疫苗可能会对伊朗宫颈癌的预防产生重大影响。综上所述,本荟萃分析强调了在伊朗引入疫苗接种计划的必要性。